Daniel Grau, an experienced biotech entrepreneur and operating executive, currently serves as CEO, President, and Director at Avilar Therapeutics, a leading extracellular protein degradation company. He also currently serves as an Advisor to HotSpot Therapeutics, an Advisor to RA Ventures (RA Capital Management), and on the board of directors of a neuroscience company currently in stealth mode. Prior to Avilar, Mr. Grau was CEO at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005). He also previously served as a Director at Research Alliance Corporation I (merged with POINT Biopharma), a Director at TetraGenetics (acquired by AbCellera), a member of the Product Advisory Board at Concert Pharmaceuticals, and as an Advisor to Nimbus Therapeutics. Early in his career, Mr. Grau worked with multi-national pharma companies including Pharmacia, Pharmacia & Upjohn, and Eisai as a management consultant focused on corporate strategy, M&A, and new product commercialization. Prior to management consulting, Mr. Grau was Director of Marketing & Business Development at a clinical information technology startup. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities.